Emisphere Technologies, Inc. (OTC BB:EMIS - News) today announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have currently taken Eligen® B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken.